JMUA-18 
- 8 - 
4. Workers currently receiviny b cero ms , iiiwiunusupiJf ebi i ve drugs or 
suffering from colitis, ileitis or acti ve/chronic diarrhea will 
not be permitted to participate in these studies. 
5. Any changes in the health status of employees (e.g., peptic ulcer 
disease, pregnancy) must be reported to OMS. Disposition of 
employees with these conditions will be determined by OMS policies 
on these matters. 
6. When an employee terminates or the work is completed, a final serum 
sample will be collected two months later and evaluated for polyoma 
HI antibodies. 
D. OMS has agreed to maintain employee medical records, including a permanent 
mailing address, for at least 20 years following the cessation of these 
research activities. 
VIII. RADIOISOTOPES 
A. Radioisotopes and/or radiolabeled nucleic acids will be used in two 
separate phases of the P4 experimentation. The regulations described 
in the Atomic Energy Act of 1954 as published in the Code of Federal 
Regulations: Title 10, Chapter 1, Parts 19, 20 and 30 will be followed. 
1. The principal investigator (Dr. Malcolm Martin) has an NIH license 
(336) to use radioisotopes. This was granted following the 
completion of a two-week training course in 1968 and a subsequent 
one-day refresher session in 1976. 
2. Other investigators participating in the work have had training and 
work experience with radioisotopes. In addition, the investigators 
will attend a one-day course entitled, "Radiation Safety in the 
Laboratory" conducted by the Radiation Safety Branch, DRS. 
B. Description of the Experimental Use of Radioisotopes 
1. Radiolabeled P-lambda or P-plasmid recombinant DNAs will be prepared 
in appropriate liquid medium with 32 P-orthophosphate or ^-thymidine. 
Nucleic acids will be removed from the Class III cabinet when it has 
been demonstrated that such preparations are sterile (see IX(B)l). 
2. Fragmented, ^^P-labeled polyoma DNA will be used as a probe in the 
colony hybridization procedure (Grunstein and Hogness, Proc. Nat. 
Acad. Sci.: U.S.A., 72, 3961-3965, 1975). 
C. . Quantities of Radioisotopes to be Used 
1. 3I?P-orthophosphate--not to exceed 6 mCi/week. 
2. ^H-thymidine --not to exceed 2 mCi/week. 
[Appendix C — 238] 
